Publication | Closed Access

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Breast OncologyEndocrine-related CancerTaselisib VersusMedicineGynecologyBreast CancerMenopausePharmacotherapyMenopause Hormone TherapyOncologyRadiation OncologyEarly-stage Breast CancerWomen's HealthPostmenopausal Women